Crossmark

Impact of timing of continuous intravenous anesthetic drug treatment on outcome in refractory status epilepticus

Crossref DOI link: https://doi.org/10.1186/s13054-018-2235-2

Published Online: 2018-11-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Madžar, Dominik

Reindl, Caroline

Giede-Jeppe, Antje

Bobinger, Tobias

Sprügel, Maximilian I.

Knappe, Ruben U.

Hamer, Hajo M.

Huttner, Hagen B.
License Information

Text and Data Mining valid from 2018-11-21
More Information

Article History

Received: 26 July 2018

Accepted: 15 October 2018

First Online: 21 November 2018

Ethics approval and consent to participate

: The study was approved by the local ethics committee of the Friedrich-Alexander University Erlangen-Nürnberg (FAU), Germany (vote number: 48_15Bc). Given the retrospective nature of the study, the need for informed consent was waived.

: Not applicable.

: HBH and DM received unrestricted grants from UCB Pharma. HMH received grants from the EU and served on the scientific advisory boards of Cerbomed, Desitin, Eisai, Bial, and UCB Pharma. He received personal fees from IQWiG. He served on the speakers’ bureau of or received unrestricted grants from Desitin, Eisai, Novartis, Bial, Hexal, Boehringer Ingelheim, and UCB Pharma. CR, AGJ, TB, MIS, and RUK declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.